Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash & Equivalents (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Cash & Equivalents for 13 consecutive years, with $198.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 98.66% to $198.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $198.7 million, a 98.66% increase, with the full-year FY2025 number at $198.7 million, up 98.66% from a year prior.
  • Cash & Equivalents was $198.7 million for Q4 2025 at Madrigal Pharmaceuticals, down from $295.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $622.5 million in Q1 2024 to a low of $33.5 million in Q2 2021.
  • A 5-year average of $165.8 million and a median of $100.0 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: surged 814.14% in 2022, then crashed 70.5% in 2025.
  • Madrigal Pharmaceuticals' Cash & Equivalents stood at $36.3 million in 2021, then soared by 814.14% to $331.5 million in 2022, then tumbled by 69.86% to $99.9 million in 2023, then increased by 0.1% to $100.0 million in 2024, then surged by 98.66% to $198.7 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Cash & Equivalents are $198.7 million (Q4 2025), $295.7 million (Q3 2025), and $186.2 million (Q2 2025).